evaluate novo nordisk on glp-1 agonists Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies GLP-1 receptor agonists and cardiovascular

Masharani U, Kroon L (2024): Pancreatic Hormones & Antidiabetic Drugs (Chapter 41)

Front Pharmacol (2020) 11:356

Some clinical studies have shown that boosting protein during food intake may be helpful

Liraglutide in apoE / mice reduced body weight as well as suppressed macrophage-driven atherosclerosis

The incidence of antibody formation was 44% with exenatide, 8.6% with liraglutide, 69.8% with lixisenatide, 4% with albiglutide, and 1.6% with dulaglutide [48, 103-106]

144 GLP-1RAs and gastrointestinal cancers GLP-1 and its receptor agonists show some potential in the treatment of gastrointestinal cancers, although this remains an emerging area of research